Loading stock data…
$17.21-0.36 (-2.08%)
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Immunome, Inc. in the Healthcare sector is trading at $17.22 with a market capitalization of $3.1B. Wall Street consensus targets $35.20 (15 analysts), implying a +104.4% move over the next 12 months. The stock is currently 43% below its 52-week high of $30.06, remaining 24.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $4.01M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$78.14M↓ | -$59.33M↑ | -$72.86M↓ | -$60.14M↓ | -$46.48M |
| Net Income | -$73.13M↓ | -$53.84M↑ | -$69.90M↓ | -$57.46M↓ | -$43.40M |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...